AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
AptarGroup (ATR) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.2 per share a year ago.
AVY beats Q1 earnings estimates on strong volumes and cost control, with profits rising and cash flow swinging to positive despite mixed segment performance.
AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATR, BMI and BBSI have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2026.
AptarGroup, Inc. (ATR) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
AptarGroup, Inc. (ATR) Presents at Bank of America 2026 Global Agriculture and Materials Conference Transcript
Explore how AptarGroup's (ATR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
AptarGroup, Inc. (ATR) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for AptarGroup (ATR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.